NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing Clinical Development

6/26/24 9:08:02 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NRBO alert in real time by email

Get the next $NRBO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NRBO

Date	Price Target	Rating	Analyst

More analyst ratings

$NRBO
Press Releases

Fastest customizable press release news feed in the world

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date"). In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, a
11/18/24 8:01:00 AM ET
$NRBO
Biotechnology: Pharmaceutical Preparations
Health Care
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum. Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Thursday, November 14, at 1:00 pm ET. Management will also be available for one-on-one meetings during the event. Interested parties who would like to listen to the Company's presentation or request a meeting can do so after registering for the
11/13/24 8:01:00 AM ET
$NRBO
Biotechnology: Pharmaceutical Preparations
Health Care
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics $21.7 Million in Cash at End of Third Quarter Expected to Fund the Company Into the Third Quarter of 2025 Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024 Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter of 2025 Entered into a Joint Research Agreement, Together With Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 CAMBRIDGE, Mass., Nov. 7, 2024 /PRN
11/7/24 8:01:00 AM ET
$NRBO
Biotechnology: Pharmaceutical Preparations
Health Care

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple Ascending Dose Part 2 of the Phase 1 Clinical Trial of DA-1726 in the Third Quarter of 2024 Part 2 of the Phase 2a Trial of DA-1241 for the Treatment of MASH Underway After Enrollment of Part 1 Completed, With Data Expected in the Fourth Quarter of 2024 Cash of $16.0 Million, Expected to Fund the Company Into the Fourth Quarter of 2024 CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focus
5/9/24 8:01:00 AM ET
$NRBO
Biotechnology: Pharmaceutical Preparations
Health Care
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024 Received Safety Review Committee (SRC) Approval Recommending That the Two-Part Phase 2a Trial of DA-1241 for the Treatment of MASH Continue Without Modification Data from the Phase 2a Trial of DA-1241 Expected in the Second Half of 2024 Cash of $22.4 Million, Expected to Fund the Company Into the Fourth Quarter of 2024 CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseas
3/28/24 8:01:00 AM ET
$NRBO
Biotechnology: Pharmaceutical Preparations
Health Care
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of cardiometabolic diseases, today announced the appointment of Marshall Woodworth as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective March 1, 2024, following his tenure as Acting Chief Financial Officer since October 27, 2023. "Marshall's decades of experience as a Chief Financial Officer for a variety of pharmaceutical and medical device companies makes him an obvious choice to appoint as a permanent Chief Financial Officer following his tenure in the acting role
3/4/24 8:01:00 AM ET
$NRBO
Biotechnology: Pharmaceutical Preparations
Health Care

NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing Clinical Development

Chat with this insight

Recent Analyst Ratings for $NRBO

$NRBO SEC Filings

NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.

NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$NRBO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by NeuroBo Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by NeuroBo Pharmaceuticals Inc.

$NRBO Press Releases

Fastest customizable press release news feed in the world

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

$NRBO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amendment: Large owner Dong-A St Co., Ltd bought $10,000,003 worth of shares (2,544,530 units at $3.93), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4)

Large owner Dong-A St Co., Ltd bought $7,964,379 worth of shares (2,544,530 units at $3.13), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4)

$NRBO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on NeuroBo Pharmaceuticals with a new price target

$NRBO Financials

Live finance-specific insights

$NRBO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$NRBO Market Insights

Live Market Insights

$NRBO Leadership Updates

Live Leadership Updates

NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

Large owner Dong-A St Co., Ltd sold $1,526 worth of shares (407 units at $3.75), decreasing direct ownership by 0.01% to 5,347,792 units (SEC Form 4)

CEO & President Kim Hyung Heon covered exercise/tax liability with 11,467 shares, decreasing direct ownership by 15% to 66,666 units (SEC Form 4)

Amendment: Large owner Dong-A St Co., Ltd bought $10,000,003 worth of shares (2,544,530 units at $3.93), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4)

Watching NeuroBo Pharmaceuticals; Zacks Small-Cap Research Gives Stock $22 Price Valuation

NeuroBo Pharmaceuticals shares are trading higher after the company announced the dosing of the first patient in the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726.

NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing Clinical Development

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Recent Analyst Ratings for
$NRBO

$NRBO
SEC Filings

$NRBO
Large Ownership Changes

$NRBO
Press Releases

$NRBO
Insider Purchases

$NRBO
Analyst Ratings

$NRBO
Financials

$NRBO
Insider Trading

$NRBO
Market Insights

$NRBO
Leadership Updates